Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.9K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.9K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.9K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.9K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.9K
Depression: Overview01:18

Depression: Overview

1.1K
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.1K
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

822
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
822

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COMBINA: The EAAD four-level approach for depression and suicide prevention and wellbeing promotion in the community and vulnerable populations. A cross-country study protocol from the MENTBEST project.

PloS one·2026
Same author

Comparison Between Browser- and App-Based Versions of a Program for Self-Management of Mild to Moderate Depression: Log Data Analysis of a Convenience Sample.

JMIR mHealth and uHealth·2026
Same author

Study Protocol: It is time to dig deeper: A cross-country implementation mapping study of the iFightDepression® (online self-management) tool.

PloS one·2026
Same author

Distinguishing Common Digital Phenotyping and Self-Report Parameters for Monitoring and Predicting Depression: Scoping Review.

JMIR mHealth and uHealth·2026
Same author

The association between feelings of loneliness and the number of social relationships in depression: a cross-sectional study of German adults.

BMC psychiatry·2026
Same author

Effect of digital intervention in the self-management of depressive symptoms: the MENTINA trial - a study protocol for a randomised controlled parallel-group trial.

BMJ open·2026

Related Experiment Video

Updated: Mar 12, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

681

Why do stimulants not work in typical depression?

Ulrich Hegerl1,2, Tilman Hensch1

  • 11 Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany.

The Australian and New Zealand Journal of Psychiatry
|November 4, 2016
PubMed
Summary
This summary is machine-generated.

Stimulants lack proven antidepressant effects in typical depression due to arousal dysregulation. However, specific patient subgroups, like those with atypical depression exhibiting sleepiness, may benefit from stimulant treatment.

Keywords:
RCTsbrain arousaldepressionindividualized treatmentstimulants

More Related Videos

A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice
05:28

A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice

Published on: May 15, 2019

23.7K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.3K

Related Experiment Videos

Last Updated: Mar 12, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

681
A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice
05:28

A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice

Published on: May 15, 2019

23.7K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.3K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Stimulants have been explored for depression treatment for 80 years, yet robust evidence from randomized controlled trials (RCTs) is lacking.
  • Recent large RCTs aiming to establish stimulants as add-on treatments for depression have failed, halting regulatory filings.
  • A key challenge is the conflation of distinct fatigue states in depression: sleepiness (arousal downregulation) versus exhaustion with inner tension (arousal upregulation).

Purpose of the Study:

  • To investigate the potential of stimulants as therapeutics for depression.
  • To explore the role of arousal dysregulation in depression and its implications for stimulant efficacy.
  • To identify potential patient subgroups who might respond to stimulant treatment based on arousal levels.

Main Methods:

  • Review of existing evidence regarding stimulant efficacy in depression.
  • Analysis of the psychopathology of fatigue in depression, differentiating between arousal downregulation and upregulation.
  • Discussion of the arousal regulation model of affective disorders.
  • Introduction of the Vigilance Algorithm Leipzig (VAL) as an electroencephalography-based biomarker for arousal assessment.

Main Results:

  • Stimulants are unlikely to benefit patients with upregulated arousal, a feature of typical depression.
  • Patients with atypical depression, characterized by sleepiness and lack of drive (arousal downregulation), may represent a subgroup responsive to stimulants.
  • The VAL algorithm shows promise for identifying these specific patient subgroups.

Conclusions:

  • The general efficacy of stimulants for depression remains unproven due to a lack of specific antidepressant effects.
  • Distinguishing between arousal upregulation and downregulation is crucial for understanding stimulant response in depression.
  • Biomarkers like arousal assessment could enable personalized stimulant therapy for specific depression subtypes.